J 2023

Increasing incidence rate of breast cancer in cystic fibrosis-relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens

ŠŤASTNÁ, Nela, Kristián BRAT, Lukáš HOMOLA, Audun OS, Dagmar BRANČÍKOVÁ et. al.

Basic information

Original name

Increasing incidence rate of breast cancer in cystic fibrosis-relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens

Authors

ŠŤASTNÁ, Nela (203 Czech Republic, guarantor, belonging to the institution), Kristián BRAT (703 Slovakia, belonging to the institution), Lukáš HOMOLA (203 Czech Republic, belonging to the institution), Audun OS and Dagmar BRANČÍKOVÁ (203 Czech Republic, belonging to the institution)

Edition

Orphanet Journal of Rare Diseases, London, England, 2023, 1750-1172

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30203 Respiratory systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.700 in 2022

RIV identification code

RIV/00216224:14110/23:00130751

Organization unit

Faculty of Medicine

UT WoS

000956257500001

Keywords in English

Cystic fibrosis; Breast cancer; Estrogens; Anticancer treatment; CFTR modulator therapy

Tags

International impact, Reviewed
Změněno: 10/5/2023 14:13, Mgr. Tereza Miškechová

Abstract

V originále

Cystic fibrosis (CF) is the most common genetic disease in the Caucasion population. Thanks to the CFTR modulators therapy, life expectancy will significantly improve. New therapeutic challenges can be expected, including diseases associated with ageing and higher incidence of cancer, as evidenced by recent epidemiological studies. The increasing incidence of tumors includes also breast cancer. The risk of breast cancer is higher in CF patients compared to the general population. Sex hormones, especially estrogens, also affect on the pathophysiology and immunology of the CF. Previous research, has demonstrated unequivocal survival rates for female CF patients compared to their male counterparts. Is demonstrated, that chemotherapy used for breast cancer affects the CFTR channel and CFTR modulator therapy has frequent side effects on breast tissue. In this review, we focus on the effects of female sex hormones on CF disease, pathophysiological relationships between CF and breast cancer, and the impact of antitumor treatment on both, malignant disease and CF. The potential for further investigation is also discussed.